Engineered nanomedicine for myeloma and bone microenvironment targeting. - Wikidata - awgldk - TriplyDB

Engineered nanomedicine for myeloma and bone microenvironment targeting.

Engineered nanomedicine for myeloma and bone microenvironment targeting.

http://www.wikidata.org/entity/Q33926003

about

Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells Exploring the tumor microenvironment with nanoparticles Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods Gold Nanocarriers for Macrophage-Targeted Therapy of Human Immunodeficiency Virus.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma The effects of proteasome inhibitors on bone remodeling in multiple myeloma.Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.Biodistribution and trafficking of hydrogel nanoparticles in adult mosquitoes.Development of individualized anti-metastasis strategies by engineering nanomedicines Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines Control of polymeric nanoparticle size to improve therapeutic delivery.Preclinical animal models of multiple myeloma Multiple myeloma in the marrow: pathogenesis and treatments.Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.Transient Canonical Wnt Stimulation Enriches Human Bone Marrow Mononuclear Cell Isolates for Osteoprogenitors.Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.Risk of vertebral compression fractures in multiple myeloma patients: A finite-element study.Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.Targeting the bone marrow microenvironment in multiple myeloma.Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering.RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Applying nanomedicine in maladaptive inflammation and angiogenesis.Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.The use of nanomaterials to treat bone infections Alendronate-decorated biodegradable polymeric micelles for potential bone-targeted delivery of vancomycin.Cancer nanomedicine: progress, challenges and opportunities.A perspective on malignancy in the marrow.Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.The scaffold microenvironment for stem cell based bone tissue engineering.Development of nanomaterials for bone-targeted drug delivery.Bone-seeking agents for the treatment of bone disorders.

P2860

Q26744596-4873C855-DC41-4780-9877-0283550EE4BD Q28082374-5656D2F1-2BC1-4D87-98C4-7EFD60B3A0E2 Q28364664-C6579D32-F69D-4431-87B0-7A567FD84AAE Q30394178-7BA80BAE-4A29-4658-879A-9606B8AC3C6C Q33856318-E75754FC-DA39-4798-939A-2F99E20059C6 Q33918020-557F6330-8BD2-4B86-B1FA-24329B667EEA Q35219539-BAE42C73-0053-4394-A9A4-669C343CA894 Q35634217-5D770914-EF49-4A33-A274-D4F62339EE31 Q35967474-27555E70-F958-4C11-B699-88BB1B1E53FA Q36034236-1A697B8A-846B-4E68-8A9D-B880AD15FA82 Q36086488-D7B3CF62-382F-481F-8A44-7AD1E306D561 Q36106734-4E881913-B78E-46B2-BC4D-8F3FC11D462B Q36186214-463EAC55-3784-4C66-84F3-73D941412BD3 Q36307555-9FC431DC-C0D5-49FE-9F4B-36F5D3252FD7 Q36561366-88B372AF-1E13-411A-BF1D-8748289E7D6E Q36725401-96212013-1208-431C-B6D7-D187AC857FDC Q36847530-18CC3860-82B5-4369-971E-8CBEAAD6579F Q36971463-31DD5BDD-3CA2-4917-97CC-200B0772BA54 Q37101382-59CCDF5B-0F25-47F0-8394-6FD5E2AC2B11 Q37169184-CC5CDD58-2522-41DC-8142-7E530CD9350C Q37175322-F0637D9B-492D-4866-BCF9-AD9E17042E90 Q37181752-81160152-76DF-4A74-B17B-F501C4F0DFAC Q37606354-0E4043CB-0824-464C-B73C-C411086A5711 Q38285398-94C9621D-F926-4770-8CAF-AD233720060E Q38289041-570D4C99-DAEE-4067-AC6D-7F78B0F378D4 Q38367669-F56D34CC-224A-4273-BF73-FA9351332DC7 Q38550480-EB490D94-0DCF-4138-BBA3-7B2BBFEB040A Q38557650-28824644-1BD5-4347-AA99-EC37C45B18E9 Q38567353-A6603BF4-F8AF-49FC-9513-715298E93168 Q38740618-94FC042D-FCD9-4A2E-B6DF-0D60DF3CA28A Q38796480-CB11C8D3-27F1-4FC3-A12D-6065F913E588 Q38861520-E466CE2C-7D9B-4570-A5C3-3B04A91B6AD8 Q38872821-079866D8-253A-42DD-B025-BE7F10706EF4 Q39005226-86DD6D68-601A-4D21-81C8-7BC8D5EB8006 Q39138403-52EF7AED-5CFB-489D-833D-9AA6AC000801 Q39138688-0D4D8C1D-5EA6-4206-B1E4-E62C8EB02191 Q39139112-CA0A6805-11EB-4BC8-B6A0-7CB444AE691A Q39266543-BA380684-2EDF-47A8-9B3F-ECDC184A1883 Q39294078-09BA7FBB-6F6F-4F6C-9EE1-7717DFDE9374 Q39356298-FC378FAB-4B39-48B0-9E63-71E2CEE33A47

P2860

Engineered nanomedicine for myeloma and bone microenvironment targeting.

http://www.wikidata.org/entity/Q33926003

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Engineered nanomedicine for myeloma and bone microenvironment targeting.

@ast

Engineered nanomedicine for myeloma and bone microenvironment targeting.

@en

type

label

Engineered nanomedicine for myeloma and bone microenvironment targeting.

@ast

Engineered nanomedicine for myeloma and bone microenvironment targeting.

@en

prefLabel

Engineered nanomedicine for myeloma and bone microenvironment targeting.

@ast

Engineered nanomedicine for myeloma and bone microenvironment targeting.

@en

P1433

Q33926003-620776C6-270F-45CB-839A-D11240C918E9

P1476

Q33926003-25D0FA48-E51F-47C8-AB9A-A1E98840FFBF

P2093

Q33926003-13CD9387-80A8-46E0-AFE3-C8656CB3443B

Q33926003-2D05BE47-F1DE-4EB3-BA82-B21983F541D6

Q33926003-40858189-FCF4-4A6F-A5CB-82FE031793E2

Q33926003-54E5E08F-D2D3-4370-9B92-39F026461290

Q33926003-5FE1D138-940C-4AA8-A5E5-3A7DD17170A7

Q33926003-612C5E39-B5B6-48A9-AF80-6A3F855D5A92

Q33926003-66724F67-FCE9-4A04-AE44-1BBCD8E8ADE0

Q33926003-6E9A0E45-C474-4F3B-B5D3-063D0D13C597

Q33926003-9232DB84-7DFD-44E0-B295-5627D8EDBCE0

Q33926003-9957880B-452F-4970-8DD0-867BCF4B3EC2

P2860

Q33926003-00DD8C0A-4F8D-4CE7-8A2D-3C45B12EA9AE

Q33926003-0131880B-E83D-47FE-87AE-697B903F2DFE

Q33926003-0DB8223B-4D9B-40EA-84AE-DF3E656C061B

Q33926003-1993386A-05C7-49C8-B3B6-E8FED1DCEB07

Q33926003-1CF550ED-70CD-4486-BC09-359AE78BEF09

Q33926003-1D5073E7-EC98-43C0-9661-B0F7CBA56EC9

Q33926003-27CBD190-0E37-46D8-A876-E2D0E1BE5103

Q33926003-3429C28A-E89D-48EE-A816-FDCE6308DC08

Q33926003-34B1EE4D-02DA-428B-8B16-D9BDA05522E0

Q33926003-38015C2E-DA97-4914-A736-7E2F518E5FC3

P304

Q33926003-1E609720-BC6A-4B4A-B565-0E7DCCAE96A6

P31

Q33926003-CF292145-A1EF-415F-8552-6344A65D6BE7

P356

Q33926003-31CD1076-A122-47F0-A83B-3CF5BD0866A8

P407

Q33926003-6A404AB4-0504-4FC1-BB7A-FE11CE051311

P433

Q33926003-7ED8962C-EFED-4524-B05F-F742A4C7331D

P478

Q33926003-EEDC3F84-FB9C-458C-AE4D-3B5BD03A8589

P50

Q33926003-01BC5AF7-0236-42CD-9929-117AF0AACAF6

Q33926003-6C2269E8-5238-4D90-8B84-8327754EBE75

Q33926003-89EC0967-1825-4FC2-B823-E191B9A16354

Q33926003-CD83B432-BE6D-40CA-9C00-92966491645A

Q33926003-D1456863-7613-4FA6-9274-868EFE79D0C5

Q33926003-E2B89173-BDEC-4ACF-8A1B-D8165A681AF2

Q33926003-E67AD223-59E4-4FFF-A6D1-E4BA6737A178

P577

Q33926003-32BCD6F2-F5A6-4EFF-ACD0-989E5EF90797

P5875

Q33926003-79B7E397-1AB5-420E-99FB-3437C114E692

P698

Q33926003-E3E41139-9E6E-42F4-8AAB-F93B6F1CDF59

P932

Q33926003-37FB70C1-99E4-45DD-85F0-97117AA5B5B3

P356

PNAS.1401337111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Engineered nanomedicine for myeloma and bone microenvironment targeting

@en

P2093

Archana Swami

http://www.w3.org/2001/XMLSchema#string

Dushanth Seevaratnam

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

Jinhe Liu

http://www.w3.org/2001/XMLSchema#string

Jinjun Shi

http://www.w3.org/2001/XMLSchema#string

Jun Wu

http://www.w3.org/2001/XMLSchema#string

Kenichi Nagano

http://www.w3.org/2001/XMLSchema#string

Masoumeh Memarzadeh

http://www.w3.org/2001/XMLSchema#string

Michele Moschetta

http://www.w3.org/2001/XMLSchema#string

Roland Baron

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-κB activity and tumor growth in murine models of multiple myeloma.

Silica nanoparticles sensitize human multiple myeloma cells to snake (Walterinnesia aegyptia) venom-induced apoptosis and growth arrest

P304

10287-10292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1401337111

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Michaela R. Reagan

Omid C. Farokhzad

Nicolas Bertrand

P577

2014-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263506335

http://www.w3.org/2001/XMLSchema#string

P698

24982170

http://www.w3.org/2001/XMLSchema#string

P932

4104924

http://www.w3.org/2001/XMLSchema#string